Real-world data indicated ART with DTG+3TC was effective and well tolerated among patients with HIV infection regardless of prior ART exposure.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Demonstrators gathered Thursday on the steps of the Department of Health and Human Services (HHS) building for a “die-in” ...

The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

The Center in Asbury Park wants people to "Come Early, Stand Proud, and Walk Strong" on May 4 for the New Jersey AIDS Walk ...

A KFF Health News analysis underscores how the terminations have spared no part of the country, politically or geographically ...

A modeling study looked at how anticipated cuts to international HIV funding would affect the rate of new cases and ...

A 10-year-old girl who'll keep going to the local clinic for the medications to suppress the HIV virus — forgetting that it's ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating lenacapavir, a long-lasting HIV prevention and treatment drug.

Young people still face high HIV risks despite PrEP Learn why prevention efforts must center Gen Z for a healthier future.

The Wayne Theatre prepares to take audiences back to the 1990s and the height of the HIV/AIDS epidemic in the United States.